A prospective, randomized, monocentric, rater blinded study evaluating the change of the cutaneous microbiome in correlation to the efficacy of cold atmospheric plasma treatment in comparison to diclofenac 3% in 2.5% hyaluronic acid (Solaraze 3% Gel) in patients with actinic keratoses - ACTICAP

Trial Profile

A prospective, randomized, monocentric, rater blinded study evaluating the change of the cutaneous microbiome in correlation to the efficacy of cold atmospheric plasma treatment in comparison to diclofenac 3% in 2.5% hyaluronic acid (Solaraze 3% Gel) in patients with actinic keratoses - ACTICAP

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Diclofenac/hyaluronic-acid (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Acronyms ACTICAP
  • Most Recent Events

    • 21 Dec 2017 Last checked against German Clinical Trials Register record.
    • 13 Dec 2017 New trial record
    • 04 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top